Royal Philips' CEO Roy Jakobs reported an improved operational performance for the healthtech and personal health company in the second quarter of 2023 − the third in a row – with comparable sales growth of 9%. The improvement was generated across all divisions and regions, he said.
Consent Decree Looms As Philips Scores Q2 Growth In A Far From 'Business-As-Usual' Year
Embattled Healthtech Says Agile Operating Model And Restructuring Plans Remain On Track
Market uncertainties caused by macro events and the Respironics recall put their imprint on Philips’ second quarter of 2023, but the company secured high single-digit growth, reported robust order bookings and increased full-year revenue guidance.
More from Recalls
• By
In discussing FDA’s adverse event monitoring, Makary also seemed to falsely imply the agency did not fully investigate the myocarditis signal with COVID-19 vaccines.
• By
The US FDA continues to issue early alerts as part of its communications pilot aimed at improving how the agency manages recalls. This time, the agency is notifying users about two separate intravascular catheters.
• By
The US FDA has issued an early alert about the CVAC system from Calyxo, which urologists use in removing urinary stones.
• By
The company is recalling Pipeline Vantage 021 and 027 models because they pose a higher than normal risk of failing to properly attach to blood vessel walls, which can cause thrombosis, stroke or death. The recall for 027 is a product removal and for 021 is an update to the instructions for use.
More from Policy & Regulation
• By
Precision’s recent FDA clearance for a core part of its next-generation wireless brain-computer interface system opens the pathway to a safer, more humane BCI for researchers to use compared to higher-risk intracortical arrays, according to BCI expert Naveen Rao.
• By
The preliminary White House 2026 budget plan cuts agency funding, but not so sharply that user fees are excluded from collection.
• By
Abbott and J&J reassured investors they will maintain their 2025 profit forecasts. Abbott projects $5.05 to $5.25 per share and plans a new $500m investment in manufacturing and R&D sites. J&J anticipates $400m in tariff-related costs but committed $55bn in US investment over four years.